CA2386411A1 - Utilisation de comme inhibiteurs de la caspase-3 nicotinyl aspartyl ketones as inhibitors of caspase-3 - Google Patents
Utilisation de comme inhibiteurs de la caspase-3 nicotinyl aspartyl ketones as inhibitors of caspase-3 Download PDFInfo
- Publication number
- CA2386411A1 CA2386411A1 CA002386411A CA2386411A CA2386411A1 CA 2386411 A1 CA2386411 A1 CA 2386411A1 CA 002386411 A CA002386411 A CA 002386411A CA 2386411 A CA2386411 A CA 2386411A CA 2386411 A1 CA2386411 A1 CA 2386411A1
- Authority
- CA
- Canada
- Prior art keywords
- 3alkyl
- 6alkyl
- aryl
- hetcy
- 4alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
L'invention concerne des composés inhibiteurs de la caspase-3 représentés par la formule générale (I), ainsi que des compositions pharmaceutiques et des méthodes de traitement. Lesdits composés sont utiles dans le traitement de maladies et d'états induits par la caspase-3, parmi lesquelles les ischémies cardiaques ou cérébrales ou les lésions dues à une reperfusion, le diabète type 1, le syndrome d'immunodéficience, y compris le SIDA, les lésions cérébrales et les traumatismes médullaires, les dommages subits par des organes lors d'une greffe, l'alopécie, le vieillissement, la maladie de Parkinson, la maladie d'Alzheimer, le syndrome de Down, la maladie d'Aran-Duchenne, la sclérose en plaques et les troubles neurodégénératifs.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15934899P | 1999-10-13 | 1999-10-13 | |
US60/159,348 | 1999-10-13 | ||
PCT/CA2000/001196 WO2001027085A1 (fr) | 1999-10-13 | 2000-10-11 | Utilisation de comme inhibiteurs de la caspase-3 nicotinyl aspartyl ketones as inhibitors of caspase-3 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2386411A1 true CA2386411A1 (fr) | 2001-04-19 |
Family
ID=22572201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002386411A Abandoned CA2386411A1 (fr) | 1999-10-13 | 2000-10-11 | Utilisation de comme inhibiteurs de la caspase-3 nicotinyl aspartyl ketones as inhibitors of caspase-3 |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU7766900A (fr) |
CA (1) | CA2386411A1 (fr) |
WO (1) | WO2001027085A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6878743B2 (en) | 2001-09-18 | 2005-04-12 | Sunesis Pharmaceuticals, Inc. | Small molecule inhibitors of caspases |
AU2003254844A1 (en) * | 2002-08-09 | 2004-02-25 | Takeda Chemical Industries, Ltd. | Substituted amino compounds and use thereof |
WO2007011760A2 (fr) * | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibiteurs de la kinesine mitotique |
IT1392238B1 (it) * | 2008-12-02 | 2012-02-22 | Fond Santa Lucia | Uso della caspasi-3 per la malattia dell'alzheimer |
CN111527139B (zh) * | 2018-02-26 | 2021-08-17 | 日本化药株式会社 | 碱增殖剂及含有该碱增殖剂的碱反应性树脂组合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69711845T2 (de) * | 1996-09-12 | 2002-10-31 | Idun Pharmaceuticals Inc | Neue tricyclische verbindungen mit ice/ced-3 protease familie-hemmenden eigenschaften |
AU755273B2 (en) * | 1998-03-16 | 2002-12-05 | Cytovia, Inc. | Dipeptide caspase inhibitors and the use thereof |
PT1064298E (pt) * | 1998-03-19 | 2009-01-02 | Vertex Pharma | Inibidores de caspasas |
-
2000
- 2000-10-11 CA CA002386411A patent/CA2386411A1/fr not_active Abandoned
- 2000-10-11 WO PCT/CA2000/001196 patent/WO2001027085A1/fr active Application Filing
- 2000-10-11 AU AU77669/00A patent/AU7766900A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU7766900A (en) | 2001-04-23 |
WO2001027085A1 (fr) | 2001-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6225288B1 (en) | Gamma-ketoacid dipeptides as inhibitors of caspase-3 | |
US6399627B1 (en) | Inhibitors of factor Xa | |
CA2378834C (fr) | Pyrazinones, compositions contenant ces composes | |
US20030114447A1 (en) | Small molecule inhibitors of caspases | |
CZ132798A3 (cs) | Inhibitory proteázy | |
KR20010005940A (ko) | 메탈로프로테이나제 억제제를 포함하는 약제학적 조성물 및 이의 약제학적 용도 | |
KR20010030945A (ko) | 펩티드 함유 α-케토아미드 시스테인 및 세린 프로테아제억제제 | |
JPH05279319A (ja) | 新規なスルホンアミド誘導体、その製造方法及びこれを含有する医薬 | |
US6686368B1 (en) | Inhibitors of factor Xa | |
CA2386411A1 (fr) | Utilisation de comme inhibiteurs de la caspase-3 nicotinyl aspartyl ketones as inhibitors of caspase-3 | |
US6552168B1 (en) | Gamma-ketoacid tetrapeptides as inhibitors of caspase-3 | |
CA2198366A1 (fr) | Nouvelles 4-aminopyridazines; methode de preparation et agents pharmaceutiques a base de ces composes | |
US6525025B2 (en) | Gamma-ketoacid dipeptides as inhibitors of caspase-3 | |
US20030045478A1 (en) | Gamma-ketoacid dipeptide derivatives as inhibitors of caspase-3 | |
US20020077455A1 (en) | Protease inhibitors | |
CZ393499A3 (cs) | Inhibitory proteasy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |